More than 635 patents filed/assigned in the last 3 years

Dublin, November 26, 2021 (GLOBE NEWSWIRE) — The report “Global Light Activated Therapies Market: Distribution by Target Indications, Key Players and Geographies: Industry Trends and Global Forecasts, 2021-2030” has been added to’s offer.

According to the World Health Organization, about 2 million to 3 million people around the world suffer from various forms of skin cancer in a year. This type of cancer accounts for 33% of all diagnosed tumors worldwide. It’s also worth emphasizing that one in five Americans is likely to develop some form of skin cancer in their lifetime. While efforts are underway to develop safe and effective drugs to treat various types of skin cancer, there is still an urgent need for more specific and potent drugs/therapies to combat this complex clinical condition.

Amid current initiatives to develop more targeted anticancer therapies, light-activated therapies (particularly photodynamic therapies, photoimmunotherapies, and photothermal therapies) have emerged as a promising alternative, due to their ability to clear diseased cells from the body. with minimal side effects. Unlike chemotherapy or radiotherapy, light-activated therapies only destroy cancer cells without damaging surrounding healthy tissues. Therefore, this new therapeutic approach has several advantages over conventional treatments for cancer and various skin diseases, such as acne, actinic keratosis, microvesicles, warts, and others.

Over time, different pharmaceutical companies have taken various initiatives to develop effective photodynamic therapies/photoimmunotherapies against multiple target indications.

Currently, the pipeline contains nearly 130 candidates and this value is expected to grow further in the near future. Of these, more than 10 therapies have already been marketed, including ASP-1929 (Rakuten Medical), VISUDYNE (Novartis), Metvix (Galderma), PHOTOFRIN (ADVANZ PHARMA), Ameluz (Biofrontera), and LEVULAN KERASTICKT (Sun Pharma).

Furthermore, more than 635 patents related to light-activated therapies have been filed/assigned in the past three years, demonstrating the continuous innovation in this field. The growing interest of pharmaceutical stakeholders in this field is also reflected in the recent proliferation of clinical trials of such drug candidates. With multiple therapeutic leads in the mid to late stages of development (Phase II and above), we are led to believe that the market for light-activated therapies is likely to see significant growth in the near future.

The report includes a comprehensive study of the current market landscape and the likely adoption of light-activated therapies over the next decade. The study contains a detailed analysis of the main drivers and trends related to this evolving domain.

The report includes:

  • A detailed assessment of the current market landscape of light-activated therapies, with regard to current development status, type of light-activated therapy, therapeutic area, type of photosensitive dye, type of light, target patient segment, type of therapy, type of developer, and popular target indications. In addition, the chapter provides an analysis of the light-activated therapy developer(s) based on several relevant parameters, including year of incorporation, company size, headquarters location and most active players.

  • Detailed profiles of marketed and advanced clinical products; each profile includes company summary, therapy overview, clinical development status, clinical trial endpoints, dosage information, key insights, clinical trial endpoints, and estimated sales revenue (2021-2030).

  • An in-depth analysis of completed, ongoing and planned clinical trials of various light-activated therapies based on relevant parameters, such as the registration year of the study, the study design and pilot phase, the type of masking and type of intervention model, the year and recruitment status of the study, type of sponsor, most active industry and non-industry players, purpose of the study, emerging area of ​​focus, location of the trial, and key geographic regions.

  • An analysis of patents filed/granted related to light-activated therapies, up to 2021.

Key questions answered

  • What are the most common R&D trends related to light-activated therapies?

  • What are the main therapeutic areas for which light-activated therapies are/have been developed?

  • What are the key challenges stakeholders face with regard to the production of light-activated therapies?

  • Who are the leading industry and non-industry players in the development of light-activated therapies?

  • In which regions is extensive research being done on light-activated therapies?

  • What factors are likely to influence the evolution of this emerging market?

  • How are current and future market opportunities likely to be distributed among key market segments?


  • Cetuximab Sarotalocan

  • Photodynamic therapy and Alacare

  • Photodynamic therapy and Ameluz

  • Photodynamic therapy and aminolevulinic acid

  • Photodynamic Therapy and Foscan (Temoporfin)

  • Photodynamic therapy and FuMeiDa (hemoporphin)

  • Photodynamic Therapy and Levulan Kerastick

  • Photodynamic Therapy and Metvixie (Metvix)

  • Photodynamic therapy and porfimer sodium / Photofrin

  • Photodynamic therapy and verteporfin (Visudyne)

  • Tookad VTP


  • Advnz Pharma

  • Biofrontera

  • Biolitec Pharma

  • Luzitin

  • Nanospectra Life Sciences

  • photoatomic

  • Rakuten Medical

  • Steba biotech

  • Theralase

For more information on this report, please visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment